Login
Login

WHY WE
NEED YOU

“ We want to stop people dying from hard-to-treat breast cancer. With your support we can make even bigger steps forward. Thank you so much for giving so kindly. ”

– Prof Roger Daly NBCF-funded researcher


Your support will fund urgent research to...

PREVENT

Understand how to prevent breast cancer based on an individuals biology, history and lifestyle. 

DETECT

Detect breast cancer as early as possible and before it progresses. 

STOP

Stop the progression and recurrence of breast cancer.

TREAT

More effectively treat hard-to-treat and metastatic breast cancers.


The funds you raise are vital for investing in world-class breast cancer research. The more you raise, the closer we get to Zero Deaths from breast cancer.

Could help support researchers to develop new therapies for hard-to-treat breast cancers

Could help support researchers to uncover more targeted and personalised treatments for hard-to-treat breast cancers with fewer side-effects.

Could help support researchers to develop a simple blood test to predict, detect and monitor the return and spread of breast cancer.

WHERE YOUR MONEY GOES

When you support the National Breast Cancer Foundation (NBCF), you’re supporting world-class research that is selected for its scientific quality and potential to contribute towards NBCFs vision of Zero Deaths from breast cancer.

These projects are funded in meritorious order via NBCF's independent and rigorous peer review system. NBCF has a number of ground-breaking research projects focusing on prevention, detecting, stopping and treating hard-to-treat and metastatic breast cancers.

Here are just a few. With your help, we can fund even more.

ASSOCIATE PROFESSOR JULIET FRENCH

QIMR Berghofer Medical Research
Project name: 

Identification of new ‘genetic’ markers of breast cancer risk and targets for RNA therapeutics.

New treatment options for hard-to-treat breast cancer subtypes including some triple negative breast cancers and breast cancers that have metastasised are desperately needed to reduce deaths from these diseases. The chances of a drug candidate succeeding through clinical trials and to the clinic dramatically increases if it is supported by robust genetic evidence. Using genetic evidence from 200,000 breast cancer survivors and healthy controls, A/Prof Juliet French and colleagues will use sophisticated large-scale laboratory tests to identify high confidence ‘genetic’ markers of breast cancer risk and targets for innovative drugs.. 

 

ASSOCIATE PROFESSOR BELINDA PARKER

Peter McCallum Cancer Centre
Project name: Using hormone targeted drugs to switch on the immune response against metastatic breast cancer

Estrogen receptor positive (+) breast cancer is treated with hormonal treatments and while some patients respond, up to 30% will develop breast cancer in distant sites with poor survival outcomes. The most common site of cancer spread after a diagnosis of ER+ breast cancer is to the bone, a cause of painful lesions occurring in up to 70% of these patients. With this NBCF support A/Prof Belinda Parker will use preclinical models of metastatic breast cancer to examine the effects of a range of standard-of-care, and alternative endocrine therapies on the immune system to reveal the best combination therapy approaches to help fight the spread of ER+ breast cancer.  


PROFESSOR ROGER DALY

Monash University 
Project name: Development of a new targeted treatment approach for triple negative breast cancers 

Triple negative breast cancer (TNBC) accounts for around 10-15% of breast cancer cases and is a highly heterogenous group of cancers, with limited targeted treatment options and poor overall survival outcomes. Prof Roger Daly and colleagues discovered a new target, Citron Rho-interacting kinase (CIT) that is responsible for the growth of a subset of TNBCs. This study will validate the potential of targeting CIT in preclinical models of TNBC and identify biomarkers of response providing the evidence needed to support the development of new drugs that can target this protein. 

ABOUT THE NATIONAL BREAST CANCER FOUNDATION

The National Breast Cancer Foundation (NBCF) is Australia’s leading national body funding world-class breast cancer research towards our vision of Zero Deaths from breast cancer. 

Since our inception in 1994, NBCF has invested over $200M into more than 600 world-class research projects across Australia.

In this time, death rates from breast cancer in Australia have improved by 43%.

We've seen remarkable results, but the job's not done.

At NBCF, we're determined to create a better tomorrow. We know research matters, and it is central and critical to improving breast cancer outcomes.

That's why we fund the very best breast cancer research in Australia by awarding grants via an open national, competitive and rigorous peer review process.

Call us on 1300 803 551

Email us